Ab­b­Vie and Al­ler­gan di­vesti­tures are in, and an old As­traZeneca drug comes home

When Ab­b­Vie an­nounced their $63-bil­lion Al­ler­gan ac­qui­si­tion last year, ex­ec­u­tives ac­knowl­edged the two com­pa­nies would have to di­vest some drugs to sat­is­fy reg­u­la­tors. The two main as­sets in dis­cus­sion have now been sold off – and one of them is com­ing home.

As­traZeneca will ac­quire brazikum­ab, Al­ler­gan’s late-stage IL-23 can­di­date for Crohn’s dis­ease and ul­cer­a­tive col­i­tis. The drug was orig­i­nal­ly de­vel­oped by As­traZeneca’s de­funct sub­sidiary Med­Im­mune, in col­lab­o­ra­tion with Am­gen. Al­ler­gan li­censed it for $250 mil­lion up­front and $1.27 bil­lion in mile­stones.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER